`

Tagged: RWE

RWE can accelerate approval timelines and reduce drug development costs as long as sponsor companies carefully uphold established evidence and engage in early dialogue with the FDA.

January 19th, 2023 | RWE

Real-world evidence (RWE) is increasingly important in clinical trial design and drug approval. RWE is clinical evidence related to patient health status and treatment safety and efficacy that are generated in clinical practice. BBCR’s team understands the role RWE plays for Natural History in Rare Diseases. We invite you to be in touch to learn […]

BBCR’s team of experts is highly experienced in the areas of Real World Evidence (RWE) for Control Arm, Post-approval Requirements and Disease Natural History. Reach out today to learn more.

September 8th, 2022 | RWE

Real-world evidence (RWE) is increasingly important in clinical trial design and drug approval. RWE is clinical evidence related to patient health status and treatment safety and efficacy that are generated in clinical practice. The FDA developed a framework to use RWE, which may combine with orphan, fast track, breakthrough therapy designation, and accelerated approval to […]

BBCR can help you better understand the role Real World Evidence (RWE) plays for natural history in rare diseases

July 13th, 2021 | RWE

Knowledge of disease and its Natural History is an essential element of any clinical development program. Real-World Data (RWD) is data relating to patient health status and/or the delivery of healthcare routinely collected from a variety of sources. Under the right conditions, data derived from real world sources can be used to build Rare diseases […]

Pin It on Pinterest